X

Drug Profile

US APR2020

Alternative Names: KT-301; US-APR2020

Latest Information Update: 06 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kibow Biotech
Class Bacteria; Probiotics; Urologics
Mechanism of Action Bacteria replacements; Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III Renal failure

Most Recent Events

12 Sep 2024 Kibow Pharma suspends phase II clinical trials in Renal failure in USA due to logistics, company reorganisation (PO) (NCT04913272)
21 Apr 2022 Phase-II/III clinical trials in Renal failure in USA (PO) (NCT05407389)
10 Mar 2022 Kibow Biotech plans to submit IND application for US APR 2020 with additional strain to the US FDA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com